METTL14 decreases FTH1 mRNA stability via m6A methylation to promote sorafenib-induced ferroptosis of cervical cancer

Lijie Li,Jie Zeng,Sili He,Yanfei Yang,Chen Wang

DOI: https://doi.org/10.1080/15384047.2024.2349429

2024-05-15

Cancer Biology & Therapy

Abstract:Cervical cancer (CC) is a prevalent malignancy among women worldwide. This study was designed to investigate the role of METTL14 in sorafenib-induced ferroptosis in CC. METTL14 expression and m6A methylation were determined in CC tissues, followed by analyzes correlating these factors with clinical features. Subsequently, METTL14 was knocked down in CC cell lines, and the effects on cell proliferation, mitochondrial morphology and ferroptosis were assessed using CCK-8, microscopy, and markers associated with ferroptosis, respectively. The regulatory relationship between METTL14 and FTH1 was verified using qRT-PCR and luciferase reporter assays. The functional significance of this interaction was further investigated both in vitro and in vivo by co-transfecting cells with overexpression vectors or shRNAs targeting METTL14 and FTH1 after sorafenib treatment. METTL14 expression and m6A methylation were significantly reduced in CC tissues, and lower METTL14 expression levels were associated with a poorer CC patients' prognosis. Notably, METTL14 expression increased during sorafenib-induced ferroptosis, and METTL14 knockdown attenuated the ferroptotic response induced by sorafenib in CC cells. FTH1 was identified as a direct target of METTL14, with METTL14 overexpression leading to increased m6A methylation of FTH1 mRNA, resulting in reduced stability and expression of FTH1 in CC. Furthermore, FTH1 overexpression or treatment with LY294002 partially counteracted the promotion of sorafenib-induced ferroptosis by METTL14. In vivo xenograft experiments demonstrated that inhibiting METTL14 reduced the anticancer effects of sorafenib, whereas suppression of FTH1 significantly enhanced sorafenib-induced ferroptosis and increased its anticancer efficacy. METTL14 reduces FTH1 mRNA stability through m6A methylation, thereby enhancing sorafenib-induced ferroptosis, which contributes to suppressing CC progression via the PI3K/Akt signaling pathway.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role and mechanism of METTL14 in sorafenib - induced ferroptosis in cervical cancer. Specifically, the researchers hope to answer this question through the following points:

1. **Relationship between METTL14 expression and clinical features**: By analyzing the expression level of METTL14 in cervical cancer tissues and its relationship with m6A methylation, explore the associations between these factors and patients' clinical features (such as tumor size, degree of differentiation, lymph node metastasis, and FIGO stage).

2. **Role of METTL14 in sorafenib - induced ferroptosis**: By knocking down or over - expressing METTL14, observe its effects on cervical cancer cell proliferation, mitochondrial morphology, and ferroptosis - related markers, and verify the function of METTL14 in sorafenib - induced ferroptosis.

3. **Interaction between METTL14 and FTH1**: Through qRT - PCR and luciferase reporter gene experiments, verify whether METTL14 regulates the stability of FTH1 mRNA through m6A methylation, thereby affecting the expression of FTH1.

4. **Mechanism of METTL14/FTH1 axis in sorafenib - induced ferroptosis**: Through in vitro and in vivo experiments, further explore the specific mechanism by which METTL14 reduces the stability of FTH1 mRNA through m6A methylation, thereby enhancing sorafenib - induced ferroptosis.

In summary, this paper aims to reveal the key role of METTL14 in sorafenib - induced ferroptosis in cervical cancer and explore its mechanism of regulating the stability of FTH1 mRNA through m6A methylation, providing new ideas for the treatment of cervical cancer.